Heterologous Ad26.COV2.S Prime and mRNA-Based Boost COVID-19 Vaccination Regimens: The SWITCH Trial Protocol.
dc.contributor.author | Sablerolles, Roos S G | |
dc.contributor.author | Goorhuis, Abraham | |
dc.contributor.author | GeurtsvanKessel, Corine H | |
dc.contributor.author | de Vries, Rory D | |
dc.contributor.author | Huckriede, Anke L W | |
dc.contributor.author | Koopmans, Marion P G | |
dc.contributor.author | Lafeber, Melvin | |
dc.contributor.author | Postma, Douwe F | |
dc.contributor.author | van Baarle, Debbie | |
dc.contributor.author | Visser, Leo G | |
dc.contributor.author | Dalm, Virgil A S H | |
dc.contributor.author | Kootstra, Neeltje A | |
dc.contributor.author | Rietdijk, Wim J R | |
dc.contributor.author | van der Kuy, P Hugo M | |
dc.date.accessioned | 2021-11-11T09:57:51Z | |
dc.date.available | 2021-11-11T09:57:51Z | |
dc.date.issued | 2021-09-24 | |
dc.identifier.pmid | 34691071 | |
dc.identifier.doi | 10.3389/fimmu.2021.753319 | |
dc.identifier.uri | http://hdl.handle.net/10029/625359 | |
dc.language.iso | en | en_US |
dc.subject | Ad26.Cov2.S | en_US |
dc.subject | BNT162.b2 | en_US |
dc.subject | COVID-19 | en_US |
dc.subject | Heterologous vaccine regimen | en_US |
dc.subject | Homologous vaccination regimen | en_US |
dc.subject | SARS-CoV-2 | en_US |
dc.subject | mRNA1273 | en_US |
dc.subject | randomized clinical trial | en_US |
dc.title | Heterologous Ad26.COV2.S Prime and mRNA-Based Boost COVID-19 Vaccination Regimens: The SWITCH Trial Protocol. | en_US |
dc.type | Article | en_US |
dc.identifier.eissn | 1664-3224 | |
dc.identifier.journal | Frontiers in immunology 2021;12:753319 | en_US |
dc.source.journaltitle | Frontiers in immunology | |
dc.source.volume | 12 | |
dc.source.beginpage | 753319 | |
dc.source.endpage | ||
dc.source.country | Switzerland |